Skip to main content
Coming in spring 2025
Woman in a medical scanner with a guiding red laser line.

Revolutionizing
immunotherapy
monitoring

Problem

Uncertain
Waiting

Cancer immunotherapy patients face three months of uncertainty about treatment effectiveness. This period of hope and anxiety needs clarity. We aim to bring certainty, reduce worry, and enhance care.

Solution

Swift Diagnosis

Our PET-Tracer tracks T-cells, enabling scans just two weeks after therapy begins to identify treatment responders. This process offers immediate results as soon as the scan is analyzed, providing early, critical insights to enhance patient care and decision-making.

How it works

Immediate
Insights

IV1 Tracer for Quick Immunotherapy Assessment: Administered two weeks post-treatment, this small protein tracer labeled with Gallium68 reveals immediate T-cell activity through a quick PET scan, enabling patients to return home shortly after. Suitable for all immunotherapy patients.

Team

Who we are

Dr. Lisa Russelli
Dr. Lisa Russelli
Radiochemist, Co-CEO
Paul Klein
Paul Klein
Economist, COO
Dr. Dario Gosmann
Dr. Dario Gosmann
Immuno-Oncologist, Co-CEO